Literature DB >> 3099852

The preparation of deglycosylated ricin by recombination of glycosidase-treated A- and B-chains: effects of deglycosylation on toxicity and in vivo distribution.

B M Foxwell, D C Blakey, A N Brown, T A Donovan, P E Thorpe.   

Abstract

Deglycosylation of ricin may be necessary to prevent the entrapment of antibody-ricin conjugates in vivo by cells of the reticuloendothelial system which have receptors that recognise the oligosaccharide side chains on the A- and B-chains of the toxin. Carbohydrate-deficient ricin was therefore prepared by recombining the A-chain, which had been treated with alpha-mannosidase, with the B-chain, which had been treated with endoglycosidase H or alpha-mannosidase or both. By recombining treated and untreated chains, a series of ricin preparations was made having different carbohydrate moieties. The removal of carbohydrate from the B-chain did not affect the ability of the toxin to agglutinate erythrocytes, and alpha-mannosidase treatment of the A-chain did not affect its ability to inactivate ribosomes. The toxicity of ricin to cells in culture was only reduced in those preparations containing B-chain that had been treated with alpha-mannosidase, when a 75% decrease in toxicity was observed. The toxicity of the combined ricin preparation to mice varied from double to half that of native ricin, depending on the chain(s) treated and the enzymes used. Removal of carbohydrate greatly reduced the hepatic clearance of the toxin and the levels of toxin in the blood were correspondingly higher. These results suggest that antibody-ricin conjugates prepared from deglycosylated ricin would be cleared more slowly by the liver, inflict less liver damage, and have greater opportunity to reach their target.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3099852     DOI: 10.1016/0304-4165(87)90126-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

1.  Influence of barrier-crossing limitations on the amount of macromolecular drug taken up by its target.

Authors:  A Aubrée-Lecat; M C Duban; S Demignot; M Domurado; P Fournié; D Domurado
Journal:  J Pharmacokinet Biopharm       Date:  1993-02

2.  Interactions of ricin with sinusoidal endothelial rat liver cells. Different involvement of two distinct carbohydrate-specific mechanisms in surface binding and internalization.

Authors:  S Magnusson; T Berg; E Turpin; J P Frénoy
Journal:  Biochem J       Date:  1991-08-01       Impact factor: 3.857

Review 3.  Potential therapeutic applications of plant toxin-ricin in cancer: challenges and advances.

Authors:  Nikhil Tyagi; Monika Tyagi; Manendra Pachauri; Prahlad C Ghosh
Journal:  Tumour Biol       Date:  2015-09-09

Review 4.  Passive and active vaccination strategies to prevent ricin poisoning.

Authors:  Seth H Pincus; Joan E Smallshaw; Kejing Song; Jody Berry; Ellen S Vitetta
Journal:  Toxins (Basel)       Date:  2011-09-15       Impact factor: 4.546

5.  A comparison of the anti-tumor effects of a chimeric versus murine anti-CD19 immunotoxins on human B cell lymphoma and Pre-B acute lymphoblastic leukemia cell lines.

Authors:  Lydia K Tsai; Laurentiu M Pop; Xiaoyun Liu; Ellen S Vitetta
Journal:  Toxins (Basel)       Date:  2011-04-06       Impact factor: 4.546

6.  Recommended Mass Spectrometry-Based Strategies to Identify Ricin-Containing Samples.

Authors:  Suzanne R Kalb; David M Schieltz; François Becher; Crister Astot; Sten-Åke Fredriksson; John R Barr
Journal:  Toxins (Basel)       Date:  2015-11-25       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.